Wockhardt Limited announced a strong recovery in its financial performance for the fiscal year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹3,373 crore and a net profit of ₹199 crore. This turnaround reflects improved operational efficiency and the successful execution of strategic initiatives, including the resolution of legal disputes and the streamlining of its global business operations to focus on core pharmaceutical strengths.
Annual Financial Performance
For the financial year ended March 31, 2026, Wockhardt Limited reported a solid consolidated annual revenue of ₹3,373 crore, compared to ₹3,012 crore in the previous year. The company successfully shifted from a net loss of ₹57 crore in the previous fiscal year to a significant consolidated net profit of ₹199 crore in FY 2026. Standalone operations also demonstrated robust health, concluding the year with a net profit of ₹317 crore.
Strategic Developments
The company’s performance was supported by key strategic milestones. Most notably, Wockhardt reached a settlement regarding a long-standing business transfer dispute with Dr. Reddy’s Laboratories Limited, resulting in a net gain of ₹35 crore. Additionally, the company has taken proactive steps to streamline its business, including the voluntary liquidation of its US generic pharmaceutical subsidiaries to focus on its primary markets. These exceptional items and the implementation of new labour codes were carefully managed to ensure long-term stability.
Future Outlook and Capital Raising
To support its future growth trajectory and capital requirements, the Board of Directors has approved a proposal to raise funds through various instruments. This includes the potential issuance of equity shares, convertible securities, or other market-permitted methods, subject to shareholder approval at the upcoming Annual General Meeting. This strategic move aims to fortify the company’s balance sheet as it continues to focus exclusively on its core pharmaceutical business segment.
Source: BSE
